BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 27693350)

  • 1. Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells.
    Boice M; Salloum D; Mourcin F; Sanghvi V; Amin R; Oricchio E; Jiang M; Mottok A; Denis-Lagache N; Ciriello G; Tam W; Teruya-Feldstein J; de Stanchina E; Chan WC; Malek SN; Ennishi D; Brentjens RJ; Gascoyne RD; Cogné M; Tarte K; Wendel HG
    Cell; 2016 Oct; 167(2):405-418.e13. PubMed ID: 27693350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A herpesvirus entry mediator mutein with selective agonist action for the inhibitory receptor B and T lymphocyte attenuator.
    Šedý JR; Balmert MO; Ware BC; Smith W; Nemčovičova I; Norris PS; Miller BR; Aivazian D; Ware CF
    J Biol Chem; 2017 Dec; 292(51):21060-21070. PubMed ID: 29061848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The HVEM-BTLA Axis Restrains T Cell Help to Germinal Center B Cells and Functions as a Cell-Extrinsic Suppressor in Lymphomagenesis.
    Mintz MA; Felce JH; Chou MY; Mayya V; Xu Y; Shui JW; An J; Li Z; Marson A; Okada T; Ware CF; Kronenberg M; Dustin ML; Cyster JG
    Immunity; 2019 Aug; 51(2):310-323.e7. PubMed ID: 31204070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia.
    M'Hidi H; Thibult ML; Chetaille B; Rey F; Bouadallah R; Nicollas R; Olive D; Xerri L
    Am J Clin Pathol; 2009 Oct; 132(4):589-96. PubMed ID: 19762537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The BTLA-HVEM axis restricts CAR T cell efficacy in cancer.
    Guruprasad P; Carturan A; Zhang Y; Cho JH; Kumashie KG; Patel RP; Kim KH; Lee JS; Lee Y; Kim JH; Chung J; Joshi A; Cohen I; Shestov M; Ghilardi G; Harris J; Pajarillo R; Angelos M; Lee YG; Liu S; Rodriguez J; Wang M; Ballard HJ; Gupta A; Ugwuanyi OH; Hong SJA; Bochi-Layec AC; Sauter CT; Chen L; Paruzzo L; Kammerman S; Shestova O; Liu D; Vella LA; Schuster SJ; Svoboda J; Porazzi P; Ruella M
    Nat Immunol; 2024 Jun; 25(6):1020-1032. PubMed ID: 38831106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cell intrinsic heterodimeric complexes between HVEM and BTLA determine receptivity to the surrounding microenvironment.
    Cheung TC; Oborne LM; Steinberg MW; Macauley MG; Fukuyama S; Sanjo H; D'Souza C; Norris PS; Pfeffer K; Murphy KM; Kronenberg M; Spear PG; Ware CF
    J Immunol; 2009 Dec; 183(11):7286-96. PubMed ID: 19915044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T follicular helper expansion and humoral-mediated rejection are independent of the HVEM/BTLA pathway.
    Rodriguez-Barbosa JI; Fernandez-Renedo C; Moral AMB; Bühler L; Del Rio ML
    Cell Mol Immunol; 2017 Jun; 14(6):497-510. PubMed ID: 26924526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT.
    Kojima R; Kajikawa M; Shiroishi M; Kuroki K; Maenaka K
    J Mol Biol; 2011 Nov; 413(4):762-72. PubMed ID: 21959263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High TNFRSF14 and low BTLA are associated with poor prognosis in Follicular Lymphoma and in Diffuse Large B-cell Lymphoma transformation.
    Carreras J; Lopez-Guillermo A; Kikuti YY; Itoh J; Masashi M; Ikoma H; Tomita S; Hiraiwa S; Hamoudi R; Rosenwald A; Leich E; Martinez A; Roncador G; Villamor N; Colomo L; Perez P; Tsuji NM; Campo E; Nakamura N
    J Clin Exp Hematop; 2019; 59(1):1-16. PubMed ID: 30918139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses.
    Spodzieja M; Lach S; Iwaszkiewicz J; Cesson V; Kalejta K; Olive D; Michielin O; Speiser DE; Zoete V; Derré L; Rodziewicz-Motowidło S
    PLoS One; 2017; 12(6):e0179201. PubMed ID: 28594868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic effects of B and T lymphocyte attenuator extracellular domain and heat shock protein 70 antigen peptide on cervical cancer in mouse model].
    Han LF; Qiu WM; Hu C; Wang L; Yao HX; Xiong SY; Meng M; Fang Y; Ma D
    Zhonghua Fu Chan Ke Za Zhi; 2010 Aug; 45(8):603-8. PubMed ID: 21029617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses.
    Kotsiou E; Okosun J; Besley C; Iqbal S; Matthews J; Fitzgibbon J; Gribben JG; Davies JK
    Blood; 2016 Jul; 128(1):72-81. PubMed ID: 27103745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory T cell expression of herpesvirus entry mediator suppresses the function of B and T lymphocyte attenuator-positive effector T cells.
    Tao R; Wang L; Murphy KM; Fraser CC; Hancock WW
    J Immunol; 2008 May; 180(10):6649-55. PubMed ID: 18453584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HVEM network signaling in cancer.
    Šedý JR; Ramezani-Rad P
    Adv Cancer Res; 2019; 142():145-186. PubMed ID: 30885361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T Cells Expressing CAR Equipped With Extracellular Domain of BTLA Are Effective Against HVEM-over-expressing Melanoma Cell Lines.
    Kim Y; Kim JE; Lee DY; Choi JU; Park JS; Lee HK; Choi SU; Park S; Park CH
    Anticancer Res; 2023 Aug; 43(8):3419-3427. PubMed ID: 37500142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A T Cell-B Cell Tumor-Suppressive Axis in the Germinal Center.
    Kennedy R; Klein U
    Immunity; 2019 Aug; 51(2):204-206. PubMed ID: 31433965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding.
    Spodzieja M; Kuncewicz K; Sieradzan A; Karczyńska A; Iwaszkiewicz J; Cesson V; Węgrzyn K; Zhukov I; Maszota-Zieleniak M; Michielin O; Speiser DE; Zoete V; Derré L; Rodziewicz-Motowidło S
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BTLA inhibition has a dominant role in the
    Battin C; Leitner J; Waidhofer-Söllner P; Grabmeier-Pfistershammer K; Olive D; Steinberger P
    Front Immunol; 2022; 13():956694. PubMed ID: 36081508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.
    Cai G; Freeman GJ
    Immunol Rev; 2009 May; 229(1):244-58. PubMed ID: 19426226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of T cell proliferation through the LIGHT-HVEM-BTLA cosignaling pathway.
    Cheung TC
    Recent Pat DNA Gene Seq; 2009; 3(3):177-82. PubMed ID: 19702559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.